Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Questions Raised In Vietnam About Pair Of HPV Vaccine Approvals

This article was originally published in PharmAsia News

Executive Summary

Vietnam authorities are looking into suspicions medical companies lobbied the government unethically to approve two vaccines against cervical cancer. They include Merck's Gardasil and GlaxoSmithKline's Cervarix. Vietnamese cancer associations are raising questions about the lobbying during the approval process for vaccines that may not be as effective as touted in staving off the human papilloma virus often responsible for cervical cancer. A GSK official said its application was the same it has sent to approval authorities in other countries and it made no special effort in Vietnam. But a Health Ministry official said Vietnam should consider the questions about effectiveness of both vaccines and continue to restrict it for women between ages 10 and 55. (Click here for more

You may also be interested in...



Health And Wellness Trademark Review 11 May, 2021

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Heron Overcomes Two CRLs To Win Zynrelef Approval In Post-Op Pain

The combination of bupivacaine and meloxicam will be priced at a discount to Exparel, with Heron predicting rapid uptake. Label limited to three surgery types, but analysts expect off-label use.

US FDA Preparing For Potential Bolus Of Complex Generic Applications

Increasing number of product development meetings suggests that many complex generics remain in the development stages.

UsernamePublicRestriction

Register

SC067459

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel